<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        11-174-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Paracetamol Kabi
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PARACETAMOL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        123.50
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="FRESENIUS KABI" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            FRESENIUS KABI
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 606]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALHAYA MEDICAL CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Fresenius Kabi Deutschland GmbH 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N02BE01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>This medicine is an analgesic (it relieves pain) and an antipyretic (it lowers fever).</p><p>&nbsp;</p><p>It is indicated</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for the short-term treatment of moderate pain, especially following surgery, and</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for the short-term treatment of fever.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Paracetamol Kabi</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are <strong>allergic</strong> (hypersensitive) <strong>to paracetamol</strong> or any of the other ingredients of Paracetamol Kabi (listed in section 6).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are <strong>allergic</strong> (hypersensitive) <strong>to propacetamol</strong> (another pain killer and a precursor of paracetamol).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from a <strong>severe liver disease</strong>.</p><p>&nbsp;</p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor before using Paracetamol Kabi.</p><p>&nbsp;</p><p><strong>Take special care with Paracetamol Kabi</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from a <strong>liver or kidney disease</strong>, or from <strong>alcohol abuse</strong>.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from a inherited liver function disorder called <strong>Meulengracht Gilbert&#39;s syndrome</strong>.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from <strong>glucose-6-phosphate dehydrogenase deficiency.</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking <strong>other medicines containing paracetamol</strong>.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from a <strong>severe lack of nutrition</strong> (malnutrition) or get parenteral nutrition</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from exsiccation</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; talk to your doctor or pharmacist if you are taking or will be taking flucloxacillin. There is a &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; risk of blood and fluid abnormality (high anion gap metabolic acidosis) which occurs when &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; there is an increase in plasma acidity, when paracetamol is used concomitantly with &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; flucloxacillin, particularly in certain groups of patients at risk, <em>e.g. </em>patients with severe renal &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; impairment, sepsis or malnutrition, especially if the maximum daily doses of paracetamol are &nbsp;&nbsp;&nbsp; used. High anion gap metabolic acidosis is a serious disease that must have urgent treatment.</p><p>&nbsp;</p><p>Inform your doctor before treatment if any of the above mentioned conditions apply to you.</p><p>&nbsp;</p><p>You should switch to taking pain killing tablets or syrup instead of Paracetamol Kabi as soon as is possible.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and Paracetamol Kabi</strong></p><p>You should not take<strong><em> </em></strong><strong>other medicines containing paracetamol</strong> if you are taking Paracetamol Kabi, in order not to exceed the recommended daily dose (see following section). Inform your doctor if you are taking other medicines containing paracetamol.</p><p>&nbsp;</p><p>If you are using <strong>probenecid</strong> (a medicine used for the treatment of gout) your doctor should consider reducing the dose of paracetamol you need, as probenecid increases the levels of paracetamol in your blood.</p><p>&nbsp;</p><p><strong>Salicylamide</strong> (another pain killer) may increase the levels of paracetamol in your blood and may therefore increase the risk of its toxic effects.</p><p>&nbsp;</p><p><strong>Rifampicin, isoniazid</strong><strong> (antibiotics)</strong>, <strong>barbiturates </strong>(sedatives),<strong> tricyclic antidepressants</strong> and <strong>medicines to treat epileptic fits</strong> (antiepileptics such as carbamazepine, phenytoin, phenobarbital, primidone) may reduce the analgesic and antipyretic effects of paracetamol and may increase as well as <strong>alcohol</strong> its liver toxic effects.</p><p>&nbsp;</p><p>Taking paracetamol and <strong>chloramphenicol</strong> (an antibiotic) together may prolong the action of the latter one.</p><p><u>&nbsp;</u></p><p>Please inform your doctor or pharmacist if you taking <strong>oral contraceptives</strong> as these may shorten the action of paracetamol.</p><p>&nbsp;</p><p>Taking paracetamol and<em> </em><strong>zidovudine</strong> (a medicine used to treat HIV) together may lead to an increased risk of a reduction in the number of certain white blood cells (neutropenia). This increases your risk of getting infections.</p><p>&nbsp;</p><p>Please inform your doctor or pharmacist if you are taking <strong>oral anticoagulants</strong> (substances that slow blood clotting). More check-ups to assess the effect of the anticoagulant might be needed.</p><p>&nbsp;</p><p>Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>Pregnancy and breast-feeding</u></strong></p><p>&nbsp;</p><p>If you are pregnant or breast-feeding, think you may be pregnant or planning to have a baby, ask your doctor for advice before you are given this medicine.</p><p>&nbsp;</p><p><strong>Pregnancy </strong></p><p>If necessary, Paracetamol Kabi can be used during pregnancy. You should use the lowest possible dose that reduces your pain and/or your fever and use it for the shortest time possible. Contact your doctor if the pain and/or fever are not reduced or if you need to take the medicine more often.</p><p><strong>&nbsp;</strong></p><p><strong>Breast-feeding</strong></p><p>Paracetamol Kabi may be used during breast-feeding.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Paracetamol Kabi has no influence on the ability to drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>This product is for intravenous use.</p><p>&nbsp;</p><p>Your doctor will administer Paracetamol Kabi to you. It is administered by drip (infusion).</p><p>&nbsp;</p><p>The 100&nbsp;ml vial or bag is restricted to adults, adolescents and children weighing more than 33&nbsp;kg (approximately 11&nbsp;years old).</p><p>&nbsp;</p><p>The 10 ml ampoule and the 50&nbsp;ml vial or bag is restricted to term newborn infants, infants, toddlers and children weighing less than 33&nbsp;kg.</p><p>&nbsp;</p><p>Your doctor should closely monitor you before the end of the infusion, in order to avoid air entering your vein.</p><p>&nbsp;</p><p><strong>Dosage</strong></p><p><strong>&nbsp;</strong></p><p><u>Dosing based on patient weight (please see the dosing table here below):</u></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p><strong>Patient weight</strong></p></td><td style="vertical-align:top"><p><strong>Dose per </strong></p><p><strong>administration</strong></p></td><td style="vertical-align:top"><p><strong>Volume per </strong></p><p><strong>administration</strong></p></td><td style="vertical-align:top"><p><strong>Maximum volume of Paracetamol Kabi 10 mg/ml solution for infusion per administration based on upper weight limits of group (mL)***</strong></p></td><td style="vertical-align:top"><p><strong>Maximum Daily Dose**</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>&le; 10 kg*</strong></p></td><td style="vertical-align:top"><p>7.5 mg/kg</p></td><td style="vertical-align:top"><p>0.75 mL/kg</p></td><td style="vertical-align:top"><p>7.5 mL</p></td><td style="vertical-align:top"><p>30 mg/kg</p></td></tr><tr><td style="vertical-align:top"><p><strong>&gt; 10 kg to &le; 33 kg</strong></p></td><td style="vertical-align:top"><p>15 mg/kg</p></td><td style="vertical-align:top"><p>1.5&nbsp;&nbsp; mL/kg</p></td><td style="vertical-align:top"><p>49.5 mL</p></td><td style="vertical-align:top"><p>60 mg/kg, not exceeding 2 g</p></td></tr><tr><td style="vertical-align:top"><p><strong>&gt; 33 kg to &le; 50 kg</strong></p></td><td style="vertical-align:top"><p>15&nbsp;mg/kg</p></td><td style="vertical-align:top"><p>1.5 mL/kg</p></td><td style="vertical-align:top"><p>75 mL</p></td><td style="vertical-align:top"><p>60 mg/kg, not exceeding 3 g</p></td></tr><tr><td style="vertical-align:top"><p><strong>&gt; 50 kg and with additional risk factors for hepatotoxicity</strong></p></td><td style="vertical-align:top"><p>1 g</p></td><td style="vertical-align:top"><p>100 mL</p></td><td style="vertical-align:top"><p>100 mL</p></td><td style="vertical-align:top"><p>3 g</p></td></tr><tr><td style="vertical-align:top"><p><strong>&gt; 50 kg and no additional risk factors for hepatotoxicity</strong></p></td><td style="vertical-align:top"><p>1 g</p></td><td style="vertical-align:top"><p>100 mL</p></td><td style="vertical-align:top"><p>100 mL</p></td><td style="vertical-align:top"><p>4 g</p></td></tr></tbody></table><p>&nbsp;</p><p>*<strong>Pre-term newborn infants:</strong> No safety and efficacy data are available for pre-term newborn infants **<strong>Maximum daily dose: </strong>The maximum daily dose as presented in the table above is for patients that are not receiving other paracetamol containing products and should be adjusted accordingly taking such products into account.</p><p>***<strong>Patients weighing less will require smaller volumes. </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>The minimum interval between each administration must be at least 4 hours in patients with normal renal function</strong><strong>. </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>The minimum interval between each administration in patients with severe renal insufficiency must be at least 6 hours.</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>The minimum interval between each administration in patients requiring haemodialysis must be at least 8 hours.</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>The maximum daily dose must not exceed 3 g in adult patients with chronic or compensated active hepatic disease, hepatocellular insufficiency, chronic alcoholism, chronic malnutrition (low reserves of hepatic glutathione), dehydration, Meulengracht Gilbert Syndrome, weighing less than 50 kg.</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>No more than 4 doses to be given in 24 hours.</strong></p><p><strong>&nbsp;</strong></p><p><em>&nbsp;</em></p><p><strong>How Paracetamol Kabi is given</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:610px"><tbody><tr><td style="vertical-align:top"><p>RISK OF MEDICATION ERRORS</p><p>Take care to avoid dosing errors due to confusion between milligram (mg) and millilitre (mL), which could result in accidential overdose and death.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>Paracetamol Kabi solution is administered as an infusion (via a drip) into your vein over 15 minutes.</p><p>An interval of at least 4 hours must be left between administrations<strong>.</strong></p><p>&nbsp;</p><p>If you have the impression that the effect of Paracetamol Kabi is too strong or too weak, talk to your doctor.</p><p>&nbsp;</p><p><strong>If you use more Paracetamol Kabi than you should</strong></p><p>If you have used more Paracetamol Kabi than you should talk to your doctor or pharmacist immediately.</p><p>&nbsp;</p><p>In overdose cases, symptoms generally appear within the first 24&nbsp;hours and comprise: nausea, vomiting, loss of appetite, paleness and belly ache. Immediate medical advice should be sought in the event of overdosage, because of the risk of irreversible liver damage.</p><p>&nbsp;</p><p>If you have any further questions on the use of this product ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Paracetamol Kabi can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong><u>Common </u></strong><u>(may affect up to </u><u>1 in 10 people)</u></p><p>pain and burning sensation at the injection site.</p><p><strong><u>Rare </u></strong><u>(may affect up to </u><u>1 in 1,000 people)</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in laboratory test results (abnormally high levels of liver enzymes found in blood tests). Should this occur, inform your doctor as regular blood tests may be required.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood pressure (hypotension)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling unwell (malaise)</p><p>&nbsp;</p><p><strong><u>Very rare </u></strong><u>(may affect </u><u>up to 1 in 10,000 people)</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduced number of certain blood cells (platelets, certain white blood cells), possibly leading to bleeding from the nose or gums and an increased risk of infections. Should these occur, inform your doctor, as regular blood tests may be required.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reactions ranging from simple skin rash or hives to severe allergic reactions (anaphylactic shock). Possible symptoms include swelling of the face, lips, tongue or other parts of the body and shortness of breath, wheezing or difficulty breathing, temporary narrowing of the airways into the lungs (bronchospasm).</p><p>If you think that Paracetamol Kabi is causing an allergic reaction, tell your doctor immediately.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Very rare cases of serious skin reactions have been reported.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Very rare cases of blood and fluid abnormality (high anion gap metabolic acidosis) which occurs when there is an increase in plasma acidity, when paracetamol is used concomitantly with flucloxacillin, generally in the presence of risk factors (see section 2).</p><p>&nbsp;</p><p><strong><u>Isolated reports </u></strong><u>(it is not known how common these are</u><u>)</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fast heart beat (tachycardia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Redness of the skin, flush, itching</p><p>&nbsp;</p><p><strong><u>Effects on laboratory tests</u></strong></p><p>Treatment with Paracetamol Kabi may alter the results of some laboratory tests for uric acid, as well as of the test for blood glucose.</p><p>&nbsp;</p><p>If any of the side effects gets serious or if you notice any side effects not listed in this leaflet, please inform your doctor or pharmacist.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor,pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p>To report any side effect(s):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Saudi Arabia:</em></strong></p><p><img alt="" src="data:image/png;base64,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" /></p><p><strong><em>UAE:</em></strong></p><p><img alt="" src="data:image/png;base64,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" /></p><ul><li><strong><em>Other GCC states</em></strong></li></ul><p><img alt="" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAjYAAAAtCAYAAAC9OCFEAAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX/tNXEAAALlSURBVHja7d1bbuJAEAXQbJ0VZilZQiYZTUYRMna1q7qB4hypPsCvfthwY6OZt8vl8vbl/as+lVJKKaWetN7/Zpp/weYTAOBZfWcZwQYAaEGwAQDaEGwAgDYEGwCgDcEGAGhDsAEA2hBsAIA2BBsAoI2pwUZQWjOBr3x8nJMAv6WCzdY/ZXy9/FUGccV+tpYLNr3OtRn9mDk2q87JV/1sAcalg83ee4JN7X4Em8dvxyP2o0Ow6TrfQL3lwWbvDs/18uiyo31m9/Hzemv50XbRvoyMy9YYn9n21tyN9nHkeJHXlXNQPffX2xyN4ehcrjw/R8b96HiV5+TWmEf65K4O8HPtLws2mfVvtW3kL8a9D9Cjdo22bWT9vXZE+pptW3Rfq+c4Owcz5j7yZZqZj+h8rRibTHuz+xwNxNF1gP6W/sZm9Lb17GAT3UfFI7ezfTnT10ywye5/5AtnpL/ZOaia++w5PivYZM/PR29vNLREzy2gr/I7NnvLt4LQ6C33M/s8au+sL47oLfOz4xltW2Z8jrY/O8fR42XnoHruK4LNyHhmtomOTfW4CzbAPS0PNhXrn/1rdGWwqXqsNtLOGeNTPce/1xkJCZ3v2FTPQfaYgg3wzB422ETvLGS+uEd+Z5FdPvM3NrPGZ8YcV43ZaD+r5j764+eqdlZsk7nujvr3aMFm9JwH+lkabH7eiz5uunULf3Sft9bd20ekH7fafdSXSDuO2n+mbZlHddlHJ6PH2pr/M3NQPffR15nzNfrIdcbYRM7VirCTvd72+iTYwGvzXypA8QWFOQDu+xkg2EDhBYXxB+5HsIHiCwrjD9yPYAMAtCHYAABtCDYAQBuCDQDQhmADALQh2AAAbQg2AEAbgg0A0IZgAwC0IdgAAG0INgBAG4INANCGYAMAtCHYAABtCDYAQBuCDQDQhmADALQh2AAAbQg2AEAbgg0A0MZ1sPn4fkMppZRS6knr43+wUUoppZTqUH8AovEbJIRs2coAAAAASUVORK5CYII=" /></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not store above 30&deg;C</p><p>&nbsp;</p><p>Keep out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use Paracetamol Kabi after the expiry date which is stated on the label and carton after EXP. The expiry date refers to the last day of the month.</p><p>&nbsp;</p><p>Do not refrigerate or freeze.</p><p>&nbsp;</p><p>Before administration, the product should be inspected visually.</p><p>Do not use Paracetamol Kabi if you notice any particles in the solution or discolouration other than slightly yellowish.</p><p>&nbsp;</p><p>Your doctor or the hospital staff will normally store Paracetamol Kabi and they are responsible for the quality of the product when it has been opened and if it is not used immediately. However, if not used immediately it should normally not be stored longer than 24 hours. After dilution, the solution should be stored no longer than 6 hours (including the infusion time). They are also responsible for disposing of any unused Paracetamol Kabi correctly.</p><p>&nbsp;</p><p>Medicines should not be disposed of via wastewater or household waste. Your doctor, nurse or pharmacist will dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Paracetamol Kabi contains</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is paracetamol. One ml contains 10&nbsp;mg paracetamol.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each 10 ml ampoule contains 100 mg paracetamol.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each 50 ml vial or bag contains 500 mg paracetamol.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each 100 ml vial or bag contains 1,000 mg paracetamol.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are cysteine, mannitol (E421), water for injections.</p><p style="margin-left:3.6pt; margin-right:0cm"><!--[if gte vml 1]><v:line id="_x0000_s1026"
 style='position:absolute;left:0;text-align:left;z-index:251662336;
 mso-position-horizontal-relative:page;mso-position-vertical-relative:page'
 from="67.75pt,69.1pt" to="527.8pt,69.1pt" strokeweight=".7pt">
 <w:wrap anchorx="page" anchory="page"/>
</v:line><![endif]--><!--[if !vml]--></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	What Paracetamol Kabi looks like and contents of the pack
Paracetamol Kabi 10 mg/ml solution for infusion is a clear and slightly yellowish solution for infusion.
Paracetamol Kabi 10 mg/ml solution for infusion is available in 10 ml glass ampoules and 50 ml or 100 ml glass vials closed with stoppers and aluminium/plastic flip-off caps and 50 ml and 100 ml bags closed with stoppers and a plastic tamper-evident covers.

Pack sizes:

Ampoules:
10 ampoules

Vials:
1 vial
10 vials
12 vials
20 vials.

Bags:
20 bags
50 bags
60 bags

Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder:</strong></p><p>&nbsp;</p><p>Fresenius Kabi Deutschland GmbH</p><p>D-61346 Bad Homburg v. d. H. / GERMANY</p><p>&nbsp;</p><p><strong>Manufacturer:</strong></p><p><strong>&nbsp;</strong></p><p>Fresenius Kabi Deutschland GmbH</p><p>Freseniusstra&szlig;e 1</p><p>D-61169 Friedberg / GERMANY</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Jan 2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">هذا الدواء هو داوء مُسكن للألم (حيث يخفف من الألم)، كما أنه دواء خافض للحرارة أيضاً (حيث يعمل على خفض الحُمى).</p><p dir="RTL">- ولذلك، عادة ما يُوصف هذا الدواء لعلاج ما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العلاج قصير الأمد للألم متوسط الحدة، خاصة بعد الخضوع لجراحة؛ و</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العلاج قصير الأمد للحُمى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا </strong><strong>يُستخدم دواء &quot;</strong><strong>باراسيتامول</strong><strong> كابي&quot; مع أي من الحالات الآتية</strong>:</p><p dir="RTL">- في حالة إن كان لديك حساسية (فرط الحساسية) تجاه مادة <strong>الباراسيتامول</strong>، أو تجاه أي من المكونات الأخرى الموجودة في دواء &quot;باراسيتامول كابي&quot; (المُدرجة في القسم 6).</p><p dir="RTL">- في حالة إن كان لديك حساسية (فرط الحساسية) تجاه مادة <strong>البروباسيتامول</strong> (وهو مُسكن آخر للألم، وأحد سلائف الباراسيتامول).</p><p dir="RTL">- في حالة إن كنت تعاني من <strong>اعتلال كبدي</strong><strong> حاد</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات والمحاذير</strong></p><p dir="RTL">لابد من استشارة الطبيب قبل استخدام دواء &quot;باراسيتامول كابي&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لابد من توخى العناية الخاصة عند استخدام</strong> <strong>دواء &quot;</strong><strong>باراسيتامول</strong><strong> كابي&quot; مع الحالات الآتية</strong>:</p><p dir="RTL">- في حالة إن كنت تعاني من اعتلال كبدي أو كلوي، أو من إفراط تعاطي الكحول.</p><p dir="RTL">- في حالة إن كنت تعاني من اضطراب وظائف الكبد الوراثي المعروف باسم &quot;متلازمة ميولينجراخت جيلبرت&quot;.</p><p dir="RTL">- في حالة إن كنت تعاني من مرض فقر الدمِ الناجم عن عوزِ سداسي فوسفات الجلوكوز النازع للهيدروجين.</p><p dir="RTL">- في حالة إن كنت تتعاطى أدوية أخرى تحتوي على مادة الباراسيتامول.</p><p dir="RTL">- في حالة إن كنت تعاني من نقص حاد في التغذية (سوء التغذية)، أو الحصول على التغذية الوريدية.</p><p dir="RTL">- في حالة إن كنت تعاني من مرض الجفاف.</p><p dir="RTL">- ولابد من استشارة الطبيب أو الصيدلي في حالة إن كنت تتعاطى حالياً أو سوف تتعاطى قريباً دواء &quot;فلوكلوكزاسيلين&quot;؛ حيث أنه عند استخدام &quot;الباراسيتامول&quot; بالتزامن مع &quot;الفلوكلوكزاسيلين&quot;، تصبح هناك خطورة لحدوث اضطراب في الدم والسوائل (ارتفاع الحماض الأيضي للفجوة الأنيونية)، والذي يحدث عند وجود ارتفاع في حموضة البلازما، وذلك لدى مجموعات معينة من المرضى المعرضين لهذا الخطر على وجه الخصوص (مثل: المرضى ممن يعانون من القصور الكلوي الحاد، أو مَرَض تَعَفُّن الدَّم، أو سوء التغذية)، وخصوصاً عند استخدام الحد الأقصى للجرعات اليومية من &quot;الباراسيتامول&quot;؛ ويعتبر &quot;ارتفاع الحماض الأيضي للفجوة الأنيونية&quot; بمثابة مرض خطير يستوجب الحصول على علاج عاجل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;ولذلك، لابد من إخبار الطبيب قبل بدء تلقي العلاج، في حالة انطباق أي من الحالات المَرَضية المذكورة أعلاه عليك؛ ففي هذه الحالة، لابد من التحول في أقرب وقت ممكن إلى تلقي أقراص أو شراب آخر مُسكن للألم، بدلاً من دواء &quot;باراسيتامول كابي&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استخدام دواء &quot;</strong><strong>باراسيتامول </strong><strong>كابي&quot; مع الأدوية </strong><strong>الأخرى</strong></p><p dir="RTL">- عند استخدام دواء &quot;باراسيتامول كابي&quot;، ينبغي عدم تعاطي أي أدوية أخرى تحتوي على مادة &quot;<strong>الباراسيتامول</strong>&quot;، وذلك من أجل عدم تجاوز الجرعة اليومية الموصى بها (انظر القسم التالي)؛ ولذلك، لابد من إخبار الطبيب في حالة تعاطي أي أدوية أخرى تحتوي على &quot;الباراسيتامول&quot;.</p><p dir="RTL">- في حالة إن كنت تتعاطى دواء &quot;<strong>بروبينسيد</strong>&quot; (وهو دواء يستخدم في علاج مرض النقرس)، لابد وأن يراعي طبيبك خفض جرعة &quot;الباراسيتامول&quot; التي تحتاج إليها؛ حيث أن دواء &quot;بروبينسيد&quot; يعمل على رفع مستويات &quot;الباراسيتامول&quot; في الدم.</p><p dir="RTL">- قد يؤدي &quot;<strong>ساليسيلاميد</strong>&quot; (مسكن آخر للألم) إلى رفع مستويات &quot;الباراسيتامول&quot; في الدم، مما يؤدي بدوره إلى زيادة مخاطر آثاره السامة.</p><p dir="RTL">- &quot;<strong>ريفامبيسين</strong>&quot; و&quot;<strong>آيزونيازيد</strong>&quot; (مضادات حيوية)، و&quot;<strong>باربيتورات</strong>&quot; (عقار مهدئ)، ومضادات الاكتئاب ثلاثية الحلقات، وأدوية علاج نوبات الصرع (مضادات الصرع، مثل: &quot;<strong>كاربامازيبين</strong>&quot;، و&quot;<strong>فينيتوين</strong>&quot;، و&quot;<strong>فينوباربيتال</strong>&quot;، و&quot;<strong>بريميدون</strong>&quot;)؛ هذه الأدوية والعقاقير قد تعمل على خفض آثار الباراسيتامول المُسكنة للألم والخافضة للحرارة، كما أنها قد تعمل أيضاً (بالإضافة إلى &quot;<strong>الكحول</strong>&quot;) على زيادة الآثار السامة للباراسيتامول على الكبد.</p><p dir="RTL">- قد يؤدي تعاطي &quot;الباراسيتامول&quot; مع &quot;<strong>كلورامفينيكول</strong>&quot; (مضاد حيوي) إلى إطالة مفعول الأخير.</p><p dir="RTL">- يُرجى استشارة الطبيب أو الصيدلي في حالة تعاطي أي من <strong>موانع الحمل</strong> عن طريق الفم، حيث أنها قد تؤدي إلى الحد من مفعول &quot;الباراسيتامول&quot;.</p><p dir="RTL">- قد يؤدي تعاطي &quot;الباراسيتامول&quot; مع &quot;<strong>زيدوفيدين</strong>&quot; (دواء يستخدم لعلاج فيروس نقص المناعة البشرية HIV)، قد يؤدي إلى زيادة خطر انخفاض عدد خلايا معينة من خلايا الدم البيضاء (اضطراب نقص الخلايا المتعادلة)؛ ويؤدي ذلك بدوره إلى زيادة خطر الإصابة بالعدوى.</p><p dir="RTL">- يُرجى استشارة الطبيب أو الصيدلي في حالة تعاطي أي من <strong>مضادات التخثر</strong> عن طريق الفم (وهي مواد تعمل على إبطاء تخثر الدم)؛ حيث أنه قد يكون هناك حاجة لإجراء مزيد من الفحوصات من أجل تقييم أثر دواء مضاد التخثر المُستخدم.</p><p dir="RTL">- لابد من استشارة الطبيب، إذا كنت تأخذ حالياً أو قد أخذت مؤخرًا أي أدوية أخرى، حتى وإن كانت أدوية تم تعاطيها دون وصفة طبيَّة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعي</strong><strong>َّ</strong><strong>ة</strong></p><p dir="RTL">إذا كنتِ حاملًا، أو ترضعين رضاعة طبيعيَّة، أو تعتقدين بأنك من المحتمل أن تكوني حاملًا، أو تخططين لإنجاب طفل، فلابد من استشارة الطبيب أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل</strong></p><p dir="RTL">من الممكن استخدام دواء &quot;باراسيتامول كابي&quot; أثناء فترة الحمل، إذا اقتضت الضرورة لذلك؛ ومع ذلك، فلابد من استخدام أقل جرعة ممكنة من أجل خفض الألم و/أو الحرارة لديكِ، مع استخدام هذا الحد الأدنى لأقصر فترة زمنية ممكنة. وفي حالة عدم انخفاض الألم و/أو الحرارة، أو في حالة الحاجة إلى تعاطي جرعة أكبر من الدواء، فلابد من استشارة الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الرضاعة الطبيعية</strong></p><p dir="RTL">من الممكن استخدام دواء &quot;باراسيتامول كابي&quot; أثناء فترة الرضاعة الطبيعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">لا توجد أي آثار لدواء &quot;باراسيتامول كابي&quot; على القدرة على القيادة واستخدام الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">- هذا المنتج مُعد للاستخدام عبر الوريد.</p><p dir="RTL">- سوف يقوم الطبيب المعالج بإعطائك دواء &quot;باراسيتامول كابي&quot;؛ ويتم تعاطي هذا الدواء عن طريق التنقيط (التسريب الوريدي).</p><p dir="RTL">- ويقتصر استخدام الكيس أو القارورة بحجم (100 مل) على المرضى من: البالغين، والمراهقين، والأطفال ممن تزيد أوزانهم على وزن 33 كجم (ممن يبلغون سن 11 عاماً تقريباً).</p><p dir="RTL">- أما الكيس أو القارورة بحجم (50 مل) والأمبولة بحجم (10 مل)، فيقتصر استخدامها على المرضى من: حديثي الولادة، والرُضع، والأطفال الصغار، والأطفال ممن تقل أوزانهم عن وزن 33 كجم.</p><p dir="RTL">- ولابد من مراعاة مراقبة الطبيب المعالج للمريض عن كثب قبل انتهاء التسريب الوريدي لمحلول الدواء، وذلك من أجل تجنب دخول أي هواء إلى وريد المريض.</p><p dir="RTL"><strong>الجرعة</strong></p><p dir="RTL"><u>يتم تحديد قدر </u><u>الجرعة </u><u>بناء على</u><u> وزن المريض (</u><u>يُرجى مراجعة جدول الجرعات الموضح</u><u> أدناه)</u>:</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:104%"><tbody><tr><td><p dir="RTL"><strong>وزن المريض</strong></p></td><td><p dir="RTL"><strong>الجرعة لكل إعطاء</strong></p></td><td><p dir="RTL"><strong>الحجم لكل إعطاء</strong></p></td><td><p dir="RTL"><strong>الحجم الأقصى لجرعة دواء &quot;باراسيتامول كابي&quot; - محلول التسريب الوريدي (10 ملجم/مل) لكل إعطاء بناء على&nbsp; حدود الوزن الأعلى للمجموعة (مل)***</strong></p></td><td><p dir="RTL"><strong>الحد الأقصى للجرعة اليومية **</strong></p></td></tr><tr><td><p dir="RTL">&le; 10 كجم*</p></td><td><p dir="RTL">7.5 ملجم/كجم</p></td><td><p dir="RTL">0.75 مل/كجم</p></td><td><p dir="RTL">7.5 مل</p></td><td><p dir="RTL">30 ملجم/كجم</p></td></tr><tr><td><p dir="RTL">&gt; 10 كجم إلى &le; 33 كجم</p></td><td><p dir="RTL">15 ملجم/كجم</p></td><td><p dir="RTL">1.5 مل/كجم</p></td><td><p dir="RTL">49.5 مل</p></td><td><p dir="RTL">60 ملجم/كجم، بما لا يتجاوز 2 جم</p></td></tr><tr><td><p dir="RTL">&gt; 33 كجم إلى &le; 50 كجم</p></td><td><p dir="RTL">15 ملجم/كجم</p></td><td><p dir="RTL">1.5 مل/كجم</p></td><td><p dir="RTL">75 مل</p></td><td><p dir="RTL">60 ملجم/كجم، بما لا يتجاوز 3 جم</p></td></tr><tr><td><p dir="RTL">&gt; 50 كجم، مع وجود عوامل خطر إضافية للإصابة بتَسَمُّمُ الكَبِد</p></td><td><p dir="RTL">1 جم</p></td><td><p dir="RTL">100 مل</p></td><td><p dir="RTL">100 مل</p></td><td><p dir="RTL">3 جم</p></td></tr><tr><td><p dir="RTL">&gt; 50 كجم، مع عدم وجود عوامل خطر إضافية للإصابة بتَسَمُّمُ الكَبِد</p></td><td><p dir="RTL">1 جم</p></td><td><p dir="RTL">100 مل</p></td><td><p dir="RTL">100 مل</p></td><td><p dir="RTL">4 جم</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">* <strong>حديثو الولادة المبتسرون</strong>: لا تتوافر أي بيانات عن سلامة وفعالية استخدام الدواء مع حديثي الولادة المبتسرين.</p><p dir="RTL">** <strong>الحد الأقصى للجرعة</strong><strong> اليومية</strong>: يتحدد الحد الأقصى للجرعة اليومية المذكور في الجدول الموضح أعلاه للمرضى الذين لا يتعاطون أي أدوية أو عقاقير أخرى تحتوي على مادة &quot;الباراسيتامول&quot;؛ وبناء على ذلك، لابد من تعديل هذا الحد الأقصى بأخذ هذه الأدوية والعقاقير الأخرى في عين الاعتبار.</p><p dir="RTL"><strong>***</strong><strong> </strong><strong>المرض</strong><strong>ى</strong><strong> الذين تكون </strong><strong>أوزانهم أقل من ذلك سوف يحتاجون إلى جرعات بأحجام أقل من ذلك.</strong></p><p dir="RTL"><strong>- لابد وأن يكون الحد الأدنى للفترة الفاصلة</strong><strong> بين كل إعطاء </strong><strong>للدواء (</strong><strong>4</strong><strong>)</strong><strong> ساعات على الأقل</strong><strong> مع المرضى ممن</strong><strong> تكون </strong><strong>وظائف الكُلى لديهم طبيعية</strong><strong>.</strong></p><p dir="RTL"><strong>- لابد وأن يكون الحد الأدنى للفترة الفاصلة بين كل إعطاء للدواء (6) ساعات على الأقل مع المرضى ممن لديهم قصور حاد في وظائف الكُلى.</strong></p><p dir="RTL"><strong>- لابد وأن يكون الحد الأدنى للفترة الفاصلة بين كل إعطاء للدواء (8) ساعات على الأقل مع المرضى ممن يخضعون لغسيل الكُلى.</strong></p><p dir="RTL"><strong>- </strong><strong>يجب ألا يتجاوز الحد الأقصى للجرعة اليومية </strong><strong>(3 جم) مع المرضى البالغين ممن يعانون من أي من الأمراض الآتية: الاعتلال الكبدي النشط المزمن أو المعوض، أو </strong><strong>قصور الخلايا الكبدية، </strong><strong>أو مرض إدمان</strong><strong> الكحول المزمن، </strong><strong>أو سوء</strong><strong> التغذية المزمن (</strong><strong>انخفاض احتياطيات الجلوتاثيون الكبدي)، أو الجفاف، أو متلازمة ميولينجراخت جيلبرت، أو أن يكون وزن المريض أقل من وزن (50 كجم).</strong></p><p dir="RTL"><strong>- يجب ألا يتم إعطاء </strong><strong>أكثر من </strong><strong>(</strong><strong>4 جرعات</strong><strong>) من الدواء خلال مدة</strong><strong> 24 ساعة.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>طريقة</strong><strong> إعطاء </strong><strong>دواء &quot;</strong><strong>باراسيتامول</strong><strong> كابي&quot;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>تحذير</strong>: مخاطر أخطاء تعاطي الأدوية</p><p dir="RTL">لابد من توخي الحرص والعناية اللازمة من أجل تجنب حدوث أي أخطاء عند تحديد الجرعة نتيجة الالتباس بين الوحدات: مليجرام (ملجم mg) ومليلتر (مل mL)، وهو ما قد يؤدي إلى تعاطي جرعة زائدة والوفاة عرضياً.</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">- يتم إعطاء محلول دواء &quot;باراسيتامول كابي&quot; عن طريق التسريب الوريدي (عبر التنقيط) في وريد المريض على مدار مدة (15) دقيقة؛ ولابد أن يكون الحد الأدنى للفترة الفاصلة بين كل إعطاء للدواء (4) ساعات على الأقل.</p><p dir="RTL">- وفي حالة إن كان لديك انطباع بأن أثر مفعول دواء &quot;باراسيتامول كابي&quot; لديك كان أقوى أو أضعف من اللازم، فلابد من استشارة الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة استخدام دواء &quot;</strong><strong>باراسيتامول </strong><strong>كابي&quot; </strong><strong>أكثر مما </strong><strong>ينبغي</strong></p><p dir="RTL">- في حالة استخدام دواء &quot;باراسيتامول كابي&quot; بشكل أكثر مما ينبغي، فلابد من استشارة الطبيب أو الصيدلي على الفور.</p><p dir="RTL">- وفي حالات تناول جرعة زائدة، عادة ما سوف تظهر الأعراض بشكل عام خلال الـ (24) ساعة الأولى؛ وتشمل هذه الأعراض كل من: الغثيان، والتقيؤ، وفقدان الشهية، والشحوب، وآلام البطن. وفي هذه الحالة، لابد من طلب الاستشارة الطبية على الفور من أجل تجنب حدوث ضرر لا يمكن علاجه بالكبد.</p><p dir="RTL">- وفي حالة إن كان لديك مزيد من الأسئلة والاستفسارات حول استخدام هذا الدواء، يمكنك الرجوع إلى الطبيب أو الصيدلي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">من الممكن أن يتسبب دواء &quot;باراسيتامول كابي&quot; في إحداث بعض الآثار الجانبيَّة مثله مثل جميع الأدوية الأخرى، وإن لم تكن هذه الآثار تصيب جميع المرضى.</p><p dir="RTL">- <strong><u>آثار شائعة</u></strong> (قد تؤثر على ما يصل إلى 1 من كل 10 أفراد): الألم والشعور بحرقة في موضع الحقن.</p><p dir="RTL">- <strong><u>آثار </u></strong><strong><u>نادرة</u></strong> (قد تؤثر على ما يصل إلى 1 من كل 1000 أفراد):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حدوث تغييرات في نتائج الاختبارات المعملية (حيث يُلاحظ وجود مستويات عالية بشكل غير طبيعي من إنزيمات الكبد في اختبارات الدم)؛ وفي حالة حدوث ذلك، لابد من إخبار الطبيب حيث قد يكون هناك حاجة لإجراء فحوصات الدم بشكل منتظم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم (هبوط ضغط الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالإعياء (التوعك).</p><p dir="RTL">- <strong><u>آثار نادرة للغاية</u></strong> (قد تؤثر على ما يصل إلى 1 من كل 10000 أفراد):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض أعداد خلايا معينة من خلايا الدم (الصفائح الدموية، وبعض خلايا الدم البيضاء)، وهو ما يمكن أن يؤدي إلى حدوث نزيف من الأنف أو اللثة، مع زيادة خطر الإصابة بالعدوى؛ وفي حالة حدوث ذلك، لابد من إخبار الطبيب، حيث قد يكون هناك حاجة لإجراء فحوصات الدم بشكل منتظم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حدوث ردود الفعل التحسسية، والتي تتراوح من الإصابة بطفح جلدي بسيط أو البثور إلى الإصابة بردود الفعل التحسسية الحادة (صدمة الحساسية). وتتضمن الأعراض المحتملة كل من: تورم الوجه أو الشفتين أو اللسان أو أجزاء أخرى من الجسم، وضيق التنفس، والصفير عند التنفس أو التنفس بصعوبة، وحدوث ضيق مؤقت بالممرات الهوائية في الرئتين (تَشَنُّجٌ قَصَبِيّ). وبالتالي، إن كنت تظن أن دواء &quot;باراسيتامول كابي&quot; يسبب لك أحد ردود الفعل التحسسية، فلابد من استشارة الطبيب على الفور.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وقد تم الإبلاغ عن حدوث حالات نادرة للغاية للإصابة بردود فعل جلدية خطيرة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كما تم الإبلاغ عن حدوث حالات نادرة للغاية للإصابة باضطراب في الدم والسوائل (ارتفاع الحماض الأيضي للفجوة الأنيونية)، والذي يحدث عند وجود ارتفاع في حموضة البلازما عند استخدام &quot;الباراسيتامول&quot; بالتزامن مع &quot;فلوكلوكساسلين&quot;، وهو ما يحدث بشكل عام عند وجود عوامل الخطورة لحدوث ذلك (انظر القسم 2).</p><p dir="RTL">- آثار من تقارير متفرقة (من غير المعروف مدى شيوع هذه الآثار):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تسارع ضربات القلب (خفقان القلب).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار الجلد، والفوران، والحكة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الآثار المحتملة على الاختبارات المعملية</p><p dir="RTL">- قد يؤدي العلاج باستخدام دواء &quot;باراسيتامول كابي&quot; إلى تغيير نتائج بعض الاختبارات المعملية فيما يتعلق بمعدلات حمض اليوريك، بالإضافة إلى اختبار قياس مستوى السكر في الدم.</p><p dir="RTL">- وفي حالة تفاقم أي من الآثار الجانبية المذكورة، أو في حالة ملاحظة ظهور أي آثار جانبية أخرى غير مدرجة في هذه النشرة، يُرجى إخبار الطبيب أو الصيدلي.</p><p dir="RTL">الإبلاغ عن الآثار الجانبيَّة</p><p dir="RTL">في حالة الإصابة بأي آثار جانبيَّة، فلابد من استشارة الطبيب أو الصيدلي أو الممرضة. ويشمل ذلك أي آثار جانبيَّة مُحتملَة غير مُدرَجَة في هذه النشرة الداخلية. كما يمكنك أيضًا الإبلاغ عن الآثار الجانبيَّة مباشرة عبر نظام الإبلاغ الوطني الساري لديك، حيث يمكنك المُساعدة في توفير مزيد من المعلومات حول سلامة هذا الدواء من خلال الإبلاغ عن هذه الآثار الجانبيَّة مباشره عن طريق نظام الإبلاغ الوطني كما هو موضح:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>المركز الوطني للتيقظ الدوائي:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مركز الاتصال الموحد: 19999</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الالكتروني: &nbsp;npc.drug@sfda.gov.sa</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الالكتروني: &nbsp;https://ade.sfda.gov.sa</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p>المملكة العربية السعودية:</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL">قسم التيقظ للمستحضرات الصيدلانية والأجهزة الطبية:</p><p dir="RTL">صندوق بريد: 1583</p><p dir="RTL">هاتف: 80011111</p><p dir="RTL">البريد الإلكتروني :&nbsp; pv@mohap.gov.ae</p><p dir="RTL">&nbsp;قسم الدواء &ndash; وزارة الصحة و وقاية المجتمع &ndash; دبي &ndash; الإمارات العربية المتحدة</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p>الإمارات العربية المتحدة:</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL">يرجى التواصل مع الجهات المختصة ذات الصلة.</p></td></tr></tbody></table><p>دول مجلس التعاون الخليجي الأخرى:</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">- يُحفظ هذا الدواء بعيدًا عن متناول أيدي الأطفال ومرمى بصرهم.</p><p dir="RTL">- لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدوَّن على الملصق الموجود على العبوة والعلبة الكرتون، ويشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر المذكور.</p><p dir="RTL">- لا تحفظ هذا الدواء في الثلاجة أو المُجمد.</p><p dir="RTL">- قبل مباشرة إعطاء الدواء، لابد من فحص المنتج بصرياً؛ حيث يجب ألا تستخدم دواء &quot;باراسيتامول كابي&quot; في حالة ملاحظة وجود أي جسيمات في المحلول، أو ملاحظة تغير لون المحلول إلى لون آخر غير لونه المائل إلى اللون الأصفر بدرجة طفيفة.</p><p dir="RTL">- وعادة ما سوف يقوم طبيبك أو طاقم العمل بالمستشفى بتخزين دواء &quot;باراسيتامول كابي&quot;، حيث تقع مسؤولية جودة المنتج على عاتقهم في حالة فتح عبوة الدواء وعدم استخدامه مباشرة على الفور. ومع ذلك، في حالة عدم استخدام الدواء على الفور، فيجب عادة ألا يتم تخزينه والاحتفاظ به لمدة تزيد على (24) ساعة؛ أما في حالة تخفيف محلول الدواء، فيجب ألا يتم الاحتفاظ بالمحلول لمدة تزيد على (6) ساعات (بما في ذلك الزمن المستغرق في عملية التسريب الوريدي). وعلاوة على ذلك، عادة ما تقع المسؤولية على عاتقهم أيضاً فيما يخص التخلص من أي عبوات غير مستخدمة من دواء &quot;باراسيتامول كابي&quot; عبر طرق التخلص الصحيحة.</p><p dir="RTL">- ولا ينبغي التخلص من أي أدوية عن طريق مياه الصرف الصحي أو في النفايات المنزليَّة، فسوف يقوم الطبيب أو الممرضة أو الصيدلي بالتخلُّص من الأدوية التي لم تعد مطلوبة؛ حيث سوف تساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="margin-left:-.1pt; margin-right:18.0pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]--></p><p dir="RTL">- المادة الفعالة في هذا الدواء هي مادة &quot;الباراسيتامول&quot;، حيث يحتوي كل مليلتر (مل) واحد من الدواء على (10) مليجرام (ملجم) من &quot;الباراسيتامول&quot;.</p><p dir="RTL">- تحتوي كل أمبولة (10 مل) على (100 ملجم) من &quot;الباراسيتامول&quot;.</p><p dir="RTL">- تحتوي كل قارورة أو كيس (50 مل) على (500 ملجم) من &quot;الباراسيتامول&quot;.</p><p dir="RTL">- تحتوي كل قارورة أو كيس (100 مل) على (1000 ملجم) من &quot;الباراسيتامول&quot;.</p><p dir="RTL">- وتشمل المكونات الأخرى كل من: السيستئين، ومانيتول (E421)، وماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">- دواء &quot;باراسيتامول كابي&quot; (محلول للتسريب الوريدي 10 ملجم/مل) هو محلول رائق مائل إلى اللون الأصفر قليلاً مُعد للتسريب الوريدي.</p><p dir="RTL">- دواء &quot;باراسيتامول كابي&quot; (محلول للتسريب الوريدي 10 ملجم/مل) هو دواء متوافر في العبوات الآتية: في أمبولات زجاجية (10 مل)، وفي قارورات زجاجية (50 مل أو 100 مل) مغلقة بسُدادة وغطاء قابل للنزع من البلاستيك/الألومنيوم، وفي أكياس (50 مل أو 100 مل) مغلقة بسُدادة وغطام مقاوم للعبث من البلاستيك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أحجام</strong> <strong>العبوات</strong>:</p><p dir="RTL">- الأمبولات:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عبوة (10 أمبولات).</p><p dir="RTL">- القارورات:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عبوة (قارورة واحدة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عبوة (10 قارورات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عبوة (12 قارورة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عبوة (20 قارورة).</p><p dir="RTL">- الأكياس:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عبوة (20 كيساً).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عبوة (50 كيساً).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عبوة (60 كيساً).</p><p dir="RTL">وقد لا يتم تسويق جميع الأحجام المذكورة للعبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركة صاحبة رخصة</strong> التسويق<strong>:</strong><strong> </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">فريزينيوس كابي دويتشلاند جي إم بي إتش</p><p dir="RTL">د-61346 باد هومبورغ ف. د . هـ / المانيا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة المُصنعة:</strong></p><p dir="RTL">فريزينيوس كابي دويتشلاند جي إم بي إتش</p><p dir="RTL">فريزينيوستراسيي 1</p><p dir="RTL">د-61169 فريدبرج / المانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يناير 2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Paracetamol 10 mg/ml solution for infusion

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1 ml contains 10 mg paracetamol.
Each 50 ml vial or bag contains 500 mg paracetamol.
Each 100 ml vial or bag contains 1000 mg paracetamol.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for infusion
Clear and slightly yellowish solution.
The solution is iso-osmotic and its pH is between 5.0 and 7.0.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Paracetamol is indicated for:<br />&bull; the short-term treatment of moderate pain, especially following surgery,<br />&bull; the short-term treatment of fever,<br />when administration by intravenous route is clinically justified by an urgent need to treat pain or hyperthermia and/or when other routes of administration are not possible.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Intravenous use.</p><p>The 100 ml vial or bag is restricted to adults, adolescents and children weighing more than 33 kg.</p><p>The 50 ml vial or bag is restricted to term newborn infants, infants, toddlers and children weighing up to 33 kg.</p><p><u>Posology: </u></p><p style="margin-left:0cm; margin-right:0cm"><u>Dosing based on patient weight (please see the dosing table here below): </u></p><p>&nbsp;</p><table cellspacing="0" cellpadding="0" border="0"><tbody><tr><td style="background-color:#e6e6e6; border-color:black; height:129.85pt; width:92.15pt"><p style="margin-left:4.3pt; margin-right:0cm"><strong>Patient weight</strong></p></td><td style="background-color:#e6e6e6; border-color:black; height:129.85pt; width:91.2pt"><p style="margin-left:3.6pt; margin-right:0cm"><strong>Dose per</strong></p><p style="margin-left:3.6pt; margin-right:0cm"><strong>administration</strong></p></td><td style="background-color:#e6e6e6; border-color:black; height:129.85pt; width:91.2pt"><p style="margin-left:3.6pt; margin-right:0cm"><strong>Volume per administration</strong></p></td><td style="background-color:#e6e6e6; border-color:black; height:129.85pt; width:91.45pt"><p style="margin-left:3.6pt; margin-right:16.2pt"><strong>Maximum volume of Paracetamol 10 mg/ml solution for infusion per administration based on upper weight limits of group (mL)***</strong></p></td><td style="background-color:#e6e6e6; border-color:black; height:129.85pt; width:92.15pt"><p style="margin-left:3.6pt; margin-right:0cm"><strong>Maximum Daily Dose**</strong></p></td></tr><tr><td style="border-color:black; height:25.45pt; width:92.15pt"><p style="margin-left:4.3pt; margin-right:0cm"><strong>&le; 10 kg*</strong></p></td><td style="height:25.45pt; width:91.2pt"><p style="margin-left:3.85pt; margin-right:0cm">7.5 mg/kg</p></td><td style="height:25.45pt; width:91.2pt"><p style="margin-left:3.85pt; margin-right:0cm">0.75 mL/kg</p></td><td style="height:25.45pt; width:91.45pt"><p style="margin-left:4.1pt; margin-right:0cm">7.5 mL</p></td><td style="height:25.45pt; width:92.15pt"><p style="margin-left:4.1pt; margin-right:0cm">30 mg/kg</p></td></tr><tr><td style="border-color:black; height:32.4pt; width:92.15pt"><p style="margin-left:4.3pt; margin-right:0cm"><strong>&gt; 10 kg to &le; 33 kg</strong></p></td><td style="height:32.4pt; vertical-align:top; width:91.2pt"><p style="margin-left:3.85pt; margin-right:0cm">15 mg/kg</p></td><td style="height:32.4pt; vertical-align:top; width:91.2pt"><p style="margin-left:3.85pt; margin-right:0cm">1.5&nbsp;&nbsp; mL/kg</p></td><td style="height:32.4pt; vertical-align:top; width:91.45pt"><p style="margin-left:4.1pt; margin-right:0cm">49.5 mL</p></td><td style="height:32.4pt; vertical-align:top; width:92.15pt"><p style="margin-left:3.6pt; margin-right:0cm">60 mg/kg, not exceeding 2 g</p></td></tr><tr><td style="border-color:black; height:32.4pt; width:92.15pt"><p style="margin-left:4.3pt; margin-right:0cm"><strong>&gt; 33 kg to &le; 50 kg</strong></p></td><td style="height:32.4pt; vertical-align:top; width:91.2pt"><p style="margin-left:3.85pt; margin-right:0cm">15 mg/kg</p></td><td style="height:32.4pt; vertical-align:top; width:91.2pt"><p style="margin-left:3.85pt; margin-right:0cm">1.5 mL/kg</p></td><td style="height:32.4pt; vertical-align:top; width:91.45pt"><p style="margin-left:4.1pt; margin-right:0cm">75 mL</p></td><td style="height:32.4pt; vertical-align:top; width:92.15pt"><p style="margin-left:3.6pt; margin-right:0cm">60 mg/kg, not exceeding 3 g</p></td></tr><tr><td style="border-color:black; height:64.3pt; vertical-align:top; width:92.15pt"><p style="margin-left:3.6pt; margin-right:0cm"><strong>&gt; 50 kg and with additional risk factors for hepatotoxicity</strong></p></td><td style="height:64.3pt; vertical-align:top; width:91.2pt"><p style="margin-left:3.85pt; margin-right:0cm">1 g</p></td><td style="height:64.3pt; vertical-align:top; width:91.2pt"><p style="margin-left:3.85pt; margin-right:0cm">100 mL</p></td><td style="height:64.3pt; vertical-align:top; width:91.45pt"><p style="margin-left:4.1pt; margin-right:0cm">100 mL</p></td><td style="height:64.3pt; vertical-align:top; width:92.15pt"><p style="margin-left:4.1pt; margin-right:0cm">3 g</p></td></tr><tr><td style="border-color:black; height:64.8pt; vertical-align:top; width:92.15pt"><p style="margin-left:3.6pt; margin-right:0cm"><strong>&gt; 50 kg and no additional risk factors for hepatotoxicity</strong></p></td><td style="height:64.8pt; vertical-align:top; width:91.2pt"><p style="margin-left:3.85pt; margin-right:0cm">1 g</p></td><td style="height:64.8pt; vertical-align:top; width:91.2pt"><p style="margin-left:3.85pt; margin-right:0cm">100 mL</p></td><td style="height:64.8pt; vertical-align:top; width:91.45pt"><p style="margin-left:4.1pt; margin-right:0cm">100 mL</p></td><td style="height:64.8pt; vertical-align:top; width:92.15pt"><p style="margin-left:4.1pt; margin-right:0cm">4 g</p></td></tr></tbody></table><p>*<strong>Pre-term newborn infants: </strong>No safety and efficacy data are available for pre-term newborn infants (see</p><p>section 5.2).</p><p>**<strong>Maximum daily dose: </strong>The maximum daily dose as presented in the table above is for patients that are not</p><p>receiving other paracetamol containing products and should be adjusted accordingly taking such products</p><p>into account.</p><p>***<strong>Patients weighing less will require smaller volumes.</strong></p><p><strong>- The minimum interval between each administration must be at least 4 hours.</strong></p><p><strong>- The minimum interval between each administration in patients with severe renal insufficiency</strong></p><p><strong>(creatinine clearance &le;30 ml/min) must be at least 6 hours.</strong></p><p><strong>- The maximum daily dose must not exceed 3 g (see section 4.4) in adults with hepatocellular</strong></p><p><strong>insufficiency, chronic alcoholism, chronic malnutrition (low reserves of hepatic glutathione),</strong></p><p><strong>dehydration</strong></p><p><strong>- No more than 4 doses to be given in 24 hours.</strong></p><p style="margin-left:0cm; margin-right:0cm"><u>Method of administration: </u></p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="_x005f_x0000_s0" o:spid="_x0000_s1026" type="#_x0000_t202"
 style='position:absolute;left:0;text-align:left;margin-left:45.6pt;
 margin-top:611.5pt;width:3.35pt;height:75.85pt;z-index:-251663872;
 mso-wrap-distance-left:0;mso-wrap-distance-right:0;
 mso-position-horizontal-relative:page;mso-position-vertical-relative:page'
 filled="f" stroked="f">
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='line-height:75.85pt;mso-line-height-rule:exactly;
    vertical-align:baseline'><span style='mso-no-proof:yes'><v:shapetype id="_x0000_t75"
     coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
     filled="f" stroked="f">
     <v:stroke joinstyle="miter"/>
     <v:formulas>
      <v:f eqn="if lineDrawn pixelLineWidth 0"/>
      <v:f eqn="sum @0 1 0"/>
      <v:f eqn="sum 0 0 @1"/>
      <v:f eqn="prod @2 1 2"/>
      <v:f eqn="prod @3 21600 pixelWidth"/>
      <v:f eqn="prod @3 21600 pixelHeight"/>
      <v:f eqn="sum @0 0 1"/>
      <v:f eqn="prod @6 1 2"/>
      <v:f eqn="prod @7 21600 pixelWidth"/>
      <v:f eqn="sum @8 21600 0"/>
      <v:f eqn="prod @7 21600 pixelHeight"/>
      <v:f eqn="sum @10 21600 0"/>
     </v:formulas>
     <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
     <o:lock v:ext="edit" aspectratio="t"/>
    </v:shapetype><v:shape id="_x0000_i1026" type="#_x0000_t75" style='width:3pt;
     height:75.75pt;visibility:visible;mso-wrap-style:square'>
     <v:imagedata src="file:///C:/Users/test/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif"
      o:title=""/>
    </v:shape></span><o:p></o:p></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="square" anchorx="page" anchory="page"/>
</v:shape><![endif]--><!--[if !vml]--><img src="file:///C:/Users/test/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" alt="Text Box:  " width="8" height="105" /><!--[endif]-->Take care when prescribing and administering Paracetamol 10 mg/ml solution for infusion to avoid dosing errors due to confusion between milligram (mg) and millilitre (mL), which could result in accidental overdose and death. Take care to ensure the proper dose is communicated and dispensed. When writing prescriptions, include both the total dose in mg and the total dose in volume. Take care to ensure the dose is measured and administered accurately.</p><p>For single use only. Any unused solution should be discarded.</p><p>Before administration, the product should be visually inspected for any particulate matter and discolouration.</p><p>The paracetamol solution is administered as a 15-minute intravenous infusion.</p><p><u>Patient weighing &le; 10 kg: </u></p><p style="margin-left:7.2pt; margin-right:0cm"><!--[if gte vml 1]><v:shape id="_x0000_s1027"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:48.95pt;margin-top:790.3pt;width:30.5pt;height:41.7pt;z-index:-251662848;
 mso-wrap-distance-left:0;mso-wrap-distance-right:0;
 mso-position-horizontal-relative:page;mso-position-vertical-relative:page'
 filled="f" stroked="f">
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='margin-top:3.85pt;margin-right:22.8pt;margin-bottom:
    30.15pt;margin-left:2.4pt;line-height:7.7pt;mso-line-height-rule:exactly;
    vertical-align:baseline'><span style='mso-no-proof:yes'><v:shape id="Picture"
     o:spid="_x0000_i1025" type="#_x0000_t75" style='width:5.25pt;height:7.5pt;
     visibility:visible;mso-wrap-style:square'>
     <v:imagedata src="file:///C:/Users/test/AppData/Local/Temp/msohtmlclip1/01/clip_image003.gif"
      o:title=""/>
    </v:shape></span><o:p></o:p></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="square" anchorx="page" anchory="page"/>
</v:shape><![endif]--><!--[if !vml]--><img src="file:///C:/Users/test/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" alt="Text Box:  " width="45" height="59" /><!--[endif]-->The glass vial or bag of Paracetamol 10 mg/ml solution for infusion should not be hung as an</p><p>infusion</p><p>due to small volume of medicinal product to be administered in this population</p><p>&nbsp;</p><p style="margin-left:36.0pt; margin-right:21.6pt; text-indent:-28.8pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->The volume to be administered should be withdrawn from the vial or bag and diluted in 0.9% sodium chloride solution or 5% glucose solution up to one tenth (one volume Paracetamol 10 mg/ml solution for infusion into nine volumes diluent) and administered over 15 minute</p><p style="margin-left:36.0pt; margin-right:32.4pt; text-indent:-28.8pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->A 5 or 10 mL syringe should be used to measure the dose as appropriate for the weight of the child and the desired volume. However, this should never exceed 7.5 mL per dose</p><p style="margin-left:36.0pt; text-indent:-28.8pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->The user should be referred to the product information for dosing guidelines</p><p>For dilution of Paracetamol 10 mg/ml solution for infusion see section 6.6.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ·	Hypersensitivity to the active substance, propacetamol hydrochloride (prodrug of paracetamol) or to any of the excipients
·	If you are allergic (hypersensitive) to paracetamol (another pain killer and a precursor of paracetamol)
·	Severe hepatocellular insufficiency (Child-Pugh >9)

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:7.2pt; margin-right:0cm"><strong>Warnings</strong></p><table cellspacing="0" cellpadding="0" border="0"><tbody><tr><td style="background-color:#d9d9d9; border-color:black; height:71.0pt; width:462.95pt"><p style="margin-left:3.6pt; margin-right:0cm">RISK OF MEDICATION ERRORS</p><p style="margin-left:3.6pt; margin-right:3.6pt; text-align:justify">Take care to avoid dosing errors due to confusion between milligram (mg) and millilitre (mL), which could result in accidental overdose and death (see section 4.2).</p></td></tr></tbody></table><p style="margin-left:7.2pt; margin-right:54.0pt">It is recommended to use a suitable analgesic oral treatment as soon as this route of administration is possible.</p><p style="margin-left:7.2pt; margin-right:46.8pt">In order to avoid the risk of overdose, check that no other medicinal products administered do contain paracetamol or propacetamol hydrochloride.</p><p style="margin-left:7.2pt; margin-right:28.8pt">Doses higher than those recommended entail the risk of very serious liver damage. Clinical signs and symptoms of hepatic damage (including fulminant hepatitis, hepatic failure, cholestatic hepatitis, cytolytic hepatitis) are not usually seen until two days, and up to a maximum of 4-6 days, after administration. Treatment with antidote should be given as soon as possible (see section 4.9).</p><p style="margin-left:7.2pt; margin-right:0cm"><u>Paracetamol should be used with particular caution under the following circumstances: </u></p><p style="margin-left:36.0pt; text-indent:-28.8pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Abnormal Liver Function and Hepatocellular insufficiency (Child-Pugh &le;9)</p><p style="margin-left:36.0pt; text-indent:-28.8pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Hepatobiliary disorders</p><p style="margin-left:36.0pt; text-indent:-28.8pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Meulengracht Gilbert Syndrome (familial non-haemolytic jaundice)</p><p style="margin-left:36.0pt; text-indent:-28.8pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Severe renal insufficiency (creatinine clearance &le;30 ml/min), see sections 4.2 and 5.2</p><p style="margin-left:36.0pt; text-indent:-28.8pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Chronic alcohol abuse</p><p style="margin-left:36.0pt; text-indent:-28.8pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Chronic malnutrition (low reserves of hepatic glutathione)</p><p style="margin-left:36.0pt; text-indent:-28.8pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Total parenteral nutrition (TPN) use</p><p style="margin-left:36.0pt; text-indent:-28.8pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Use of enzyme inducers</p><p style="margin-left:36.0pt; text-indent:-28.8pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Use of hepatotoxic agents</p><p style="margin-left:36.0pt; margin-right:50.4pt; text-indent:-28.8pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->In patients suffering from a genetically caused G-6-PD deficiency (favism) the occurrence of a haemolytic anaemia is possible due to the reduced allocation of glutathione following the administration of paracetamol.</p><p style="margin-left:36.0pt; text-indent:-28.8pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Dehydration</p><p style="margin-left:7.2pt; margin-right:0cm"><u>Effects on laboratory tests </u></p><p style="margin-left:7.2pt; margin-right:0cm">Paracetamol can affect tests for uric acid using phosphotungstic acid and blood sugar tests using glucose-</p><p style="margin-left:7.2pt; margin-right:0cm">oxidase-peroxidase.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:43.2pt; margin-right:10.8pt; text-indent:-32.4pt">.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Probenecid causes an almost 2-fold reduction in clearance of paracetamol by inhibiting its conjugation with glucuronic acid. A reduction of the paracetamol dose should be considered for concomitant treatment with probenecid</p><p style="margin-left:10.8pt; margin-right:0cm">.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Salicylamide may prolong the elimination t1/2 of paracetamol</p><p style="margin-left:10.8pt; margin-right:0cm">.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Caution should be paid to the concomitant intake of enzyme-inducing substances</p><p style="margin-left:43.2pt; margin-right:10.8pt; text-indent:-32.4pt">.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Concomitant use of paracetamol (4 g per day for at least 4 days) with oral anticoagulants may lead to slight variations of INR values. In this case, increased monitoring of INR values should be conducted during the period of concomitant use as well as for 1 week after paracetamol treatment has been discontinued.</p><p style="margin-left:43.2pt; margin-right:14.4pt; text-indent:-32.4pt">.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Rifampicin </strong>(an antibiotic), <strong>barbiturates </strong>(sedatives), <strong>tricyclic antidepressants </strong>and <strong>medicines to treat epileptic fits </strong>(antiepileptics such as carbamazepine, phenytoin, phenobarbital, primidone) may reduce the analgesic and antipyretic effects of paracetamol and may increase as well as <strong>alcohol </strong>its liver toxic effects.</p><p style="margin-left:43.2pt; margin-right:36.0pt; text-indent:-32.4pt">.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Taking paracetamol and <strong>chloramphenicol </strong>(an antibiotic) together may prolong the action of the latter one.</p><p style="margin-left:43.2pt; margin-right:18.0pt; text-indent:-32.4pt">.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please inform your doctor or pharmacist if you taking <strong>oral contraceptives </strong>as these may shorten the action of paracetamol.</p><p style="margin-left:43.2pt; margin-right:14.4pt; text-indent:-32.4pt">.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Taking paracetamol and <strong>zidovudine </strong>(a medicine used to treat HIV) together may lead to an increased risk of a reduction in the number of certain white blood cells (neutropenia). This increases your risk of getting infections.</p><p style="margin-left:43.2pt; margin-right:18.0pt; text-indent:-32.4pt">.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please inform your doctor or pharmacist if you are taking <strong>oral anticoagulants </strong>(substances that slow blood clotting). More check-ups to assess the effect of the anticoagulant might be needed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:10.8pt; margin-right:0cm"><u>Pregnancy: </u>&nbsp;</p><p style="margin-left:10.8pt; margin-right:14.4pt">Clinical experience of intravenous administration of paracetamol is limited. However, epidemiological data from the use of oral therapeutic doses of paracetamol indicate no undesirable effects on the pregnancy or on the health of the foetus / newborn infant.</p><p style="margin-left:10.8pt; margin-right:46.8pt">Prospective data on pregnancies exposed to overdoses did not show an increase in malformation risk. Reproductive studies with the intravenous form of paracetamol have not been performed in animals. However, studies with the oral route did not show any malformation of foetotoxic effects.</p><p style="margin-left:10.8pt; margin-right:10.8pt">Nevertheless, PERFALGAN should only be used during pregnancy after a careful benefit-risk assessment. In this case, the recommended posology and duration must be strictly observed.</p><p style="margin-left:10.8pt; margin-right:0cm"><u>Lactation: </u>&nbsp;</p><p style="margin-left:10.8pt">After oral administration, paracetamol is excreted into breast milk in small quantities. No undesirable effects</p><p style="margin-left:10.8pt; margin-right:0cm">on nursing infants have been reported.</p><p style="margin-left:10.8pt">Consequently, PERFALGAN may be used in breast-feeding women.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:10.8pt; margin-right:0cm">Paracetamol has no influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:10.8pt; margin-right:0cm">The evaluation of undesirable effects is based on the following definition of frequency:</p><p style="margin-left:10.8pt; margin-right:0cm">Very common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge;1/10</p><p>&nbsp;</p><p style="margin-left:7.2pt; margin-right:0cm">Common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 21/100 to &lt;1/10</p><p style="margin-left:7.2pt; margin-right:0cm">Uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 21/1,000 to &lt;1/100</p><p style="margin-left:7.2pt; margin-right:0cm">Rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 21/10,000 to &lt;1/1,000</p><p style="margin-left:7.2pt">Very rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt;1/10,000</p><p style="margin-left:7.2pt; margin-right:0cm">Not known&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Frequency cannot be estimated from the available data</p><p style="margin-left:7.2pt; margin-right:28.8pt">As with all paracetamol containing medicinal products, undesirable effects are rare or very rare. They are described in the following table:</p><table cellspacing="0" cellpadding="0" border="0"><tbody><tr><td style="background-color:#e6e6e6; border-color:black; height:25.9pt; width:123.6pt"><p style="margin-left:0cm; margin-right:15.5pt; text-align:right"><strong>System organ class</strong></p></td><td style="background-color:#e6e6e6; border-color:black; height:25.9pt; width:100.1pt"><p style="margin-left:0cm; margin-right:35.25pt; text-align:right"><strong>Rare</strong></p></td><td style="background-color:#e6e6e6; border-color:black; height:25.9pt; width:138.95pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center"><strong>Very rare</strong></p></td><td style="background-color:#e6e6e6; border-color:black; height:25.9pt; width:124.05pt"><p style="margin-left:0cm; margin-right:33.1pt; text-align:right"><strong>Not known</strong></p></td></tr><tr><td style="border-color:black; height:51.4pt; vertical-align:top; width:123.6pt"><p style="margin-left:3.6pt; margin-right:0cm">Blood and lymphatic system disorders</p></td><td style="height:51.4pt; vertical-align:top; width:100.1pt"><p>&nbsp;</p></td><td style="height:51.4pt; width:138.95pt"><p style="margin-left:3.6pt; margin-right:0cm">Thrombocytopenia, leukopenia, neutropenia, agranulocytosis</p></td><td style="height:51.4pt; vertical-align:top; width:124.05pt"><p>&nbsp;</p></td></tr><tr><td style="border-color:black; height:90.2pt; vertical-align:top; width:123.6pt"><p style="margin-left:4.3pt; margin-right:0cm">Immune system disorders</p></td><td style="height:90.2pt; vertical-align:top; width:100.1pt"><p>&nbsp;</p></td><td style="height:90.2pt; vertical-align:top; width:138.95pt"><p style="margin-left:3.6pt; margin-right:5.4pt">Hypersensitivity (ranging from simple skin rash or urticaria to anaphylactic shock which requires immediate discontinuation of treatment), bronchospasm</p></td><td style="height:90.2pt; vertical-align:top; width:124.05pt"><p>&nbsp;</p></td></tr><tr><td style="border-color:black; height:25.45pt; width:123.6pt"><p style="margin-left:4.3pt; margin-right:0cm">Cardiac disorders</p></td><td style="height:25.45pt; vertical-align:top; width:100.1pt"><p>&nbsp;</p></td><td style="height:25.45pt; vertical-align:top; width:138.95pt"><p>&nbsp;</p></td><td style="height:25.45pt; width:124.05pt"><p style="margin-left:0cm; margin-right:64.6pt; text-align:right">Tachycardia</p></td></tr><tr><td style="border-color:black; height:25.45pt; width:123.6pt"><p style="margin-left:4.3pt; margin-right:0cm">Vascular disorders</p></td><td style="height:25.45pt; width:100.1pt"><p style="margin-left:4.1pt; margin-right:0cm">Hypotension</p></td><td style="height:25.45pt; vertical-align:top; width:138.95pt"><p>&nbsp;</p></td><td style="height:25.45pt; vertical-align:top; width:124.05pt"><p>&nbsp;</p></td></tr><tr><td style="border-color:black; height:38.4pt; width:123.6pt"><p style="margin-left:3.6pt; margin-right:0cm">Skin and subcutaneous tissue disorders</p></td><td style="height:38.4pt; vertical-align:top; width:100.1pt"><p>&nbsp;</p></td><td style="height:38.4pt; vertical-align:top; width:138.95pt"><p style="margin-left:4.05pt; margin-right:0cm">serious skin reactions</p></td><td style="height:38.4pt; width:124.05pt"><p style="margin-left:3.6pt; margin-right:0cm">Erythema, flushing, pruritus</p></td></tr><tr><td style="border-color:black; height:51.35pt; width:123.6pt"><p style="margin-left:3.6pt; margin-right:0cm">General disorders and administration site conditions</p></td><td style="height:51.35pt; vertical-align:top; width:100.1pt"><p style="margin-left:4.1pt; margin-right:0cm">Malaise</p></td><td style="height:51.35pt; vertical-align:top; width:138.95pt"><p>&nbsp;</p></td><td style="height:51.35pt; vertical-align:top; width:124.05pt"><p>&nbsp;</p></td></tr><tr><td style="border-color:black; height:39.15pt; vertical-align:top; width:123.6pt"><p style="margin-left:4.3pt; margin-right:0cm">Investigations</p></td><td style="height:39.15pt; width:100.1pt"><p style="margin-left:3.6pt; margin-right:0cm">Transaminases increased</p></td><td style="height:39.15pt; vertical-align:top; width:138.95pt"><p>&nbsp;</p></td><td style="height:39.15pt; vertical-align:top; width:124.05pt"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p style="margin-left:7.2pt; margin-right:0cm"><u>Reporting of suspected adverse reactions </u></p><p style="margin-left:7.2pt; margin-right:32.4pt">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed below:</p><p style="margin-left:18.0pt; margin-right:0cm; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong><em>Saudi Arabia:</em></strong></p><table cellspacing="0" cellpadding="0" border="0"><tbody><tr><td style="border-color:black; height:89.55pt; vertical-align:top; width:390.45pt"><p style="margin-left:10.8pt; margin-right:0cm">The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p style="margin-left:28.8pt; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp; <!--[endif]-->Fax: +966-11-205-7662</p><p style="margin-left:28.8pt; margin-right:0cm; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp; <!--[endif]-->Call NPC at +966-11-2038222, Exts: 2317-2356-2340.</p><p style="margin-left:28.8pt; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp; <!--[endif]-->Toll free phone: 19999</p><p style="margin-left:28.8pt; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp; <!--[endif]-->E-mail: npc.drug@sfda.gov.sa<u> </u></p><p style="margin-left:28.8pt; margin-right:0cm; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp; <!--[endif]-->Website:<u> </u>www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;</p><p style="margin-left:10.8pt; margin-right:0cm; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong><em>Other GCC States:</em></strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0cm; margin-right:14.4pt">At particular risk for hepatic damage (including fulminant hepatitis, hepatic failure, cholestatic hepatitis, cytolytic hepatitis) are elderly patients, young children, patients with hepatic disorders, chronic alcoholism, chronic malnutrition and patients concurrently receiving medicinal products that lead to enzyme induction. In such cases, overdose may be fatal.</p><p><em><u>Symptoms of overdose </u></em></p><p>Symptoms generally appear within the first 24 hours and comprise: nausea, vomiting, anorexia, pallor</p><p>and abdominal pain.</p><p style="margin-left:0cm; margin-right:10.8pt">Overdose with 7.5 g or more of paracetamol in a single administration in adults or 140 mg/kg of body weight in a single administration in paediatric patients, leads to hepatic cell necrosis, which can cause complete and irreversible necrosis and subsequently hepatocellular insufficiency, metabolic acidosis and encephalopathy. This, in turn, can lead to coma, sometimes with fatal outcome. Simultaneously, increased levels of hepatic transaminases (AST, ALT), lactate dehydrogenase and bilirubin in combination with decreased prothrombin levels are observed, which may occur 12 to 48 hours after administration.</p><p style="margin-left:0cm; margin-right:7.2pt">Clinical symptoms of hepatic damage are usually evident after two days, and reach a maximum after 4 to 6 days.</p><p><em><u>Treatment of overdose </u></em></p><p style="margin-left:28.8pt; text-indent:-28.8pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Immediate hospitalisation</p><p style="margin-left:28.8pt; margin-right:10.8pt; text-indent:-28.8pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Before initiating treatment, and as soon as possible following the overdose, a blood sample for determination of plasma paracetamol levels should be taken.</p><p style="margin-left:28.8pt; margin-right:7.2pt; text-indent:-28.8pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->The treatment includes administration of the antidote, N-acetylcysteine (NAC) either by the intravenous or the oral route, if possible during the first 10 hours. N-acetylcysteine can also offer some degree of protection even after 10 hours, but in this case prolonged treatment will be required.</p><p style="margin-left:28.8pt; text-indent:-28.8pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Symptomatic treatment</p><p style="margin-left:28.8pt; margin-right:10.8pt; text-indent:-28.8pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Liver function tests must be carried out at the beginning of treatment and repeated every 24 hours. Usually hepatic transaminases return to normal in one to two weeks with full recovery of normal liver function. In very severe cases, however, liver transplantation may be necessary.</p><p style="margin-left:28.8pt; text-indent:-28.8pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Haemodialysis can reduce the plasma paracetamol concentration, but the effects are limited.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Other analgesics and antipyretics, anilides, ATC code: N02BE01</p><p style="margin-left:0cm; margin-right:32.4pt">The precise analgesic and antipyretic mode of action of paracetamol has not been established. A central and peripheral effect is likely.</p><p style="margin-left:0cm; margin-right:14.4pt">Paracetamol provides onset of pain relief within 5 to 10 minutes following administration. The peak analgesic effect is obtained within 1 hour and analgesia usually persists 4 to 6 hours.</p><p style="margin-left:0cm; margin-right:10.8pt">Paracetamol reduces fever within 30 minutes following administration. The antipyretic effect persists for at least 6 hours.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Adults</u></p><p><em>Absorption</em></p><p>Following single and repeated administration during 24 hours paracetamol pharmacokinetics is linear</p><p>up to 2 g.</p><p style="margin-left:0cm; margin-right:10.8pt">Bioavailability of paracetamol following infusion of 500 mg and 1 g of paracetamol is similar to that observed following infusion of 1 g and 2 g propacetamol (corresponding to 500 mg and 1 g paracetamol), respectively.</p><p style="margin-left:0cm; margin-right:18.0pt">The maximal plasma concentration (Cmax) of paracetamol observed at the end of a 15-minute intravenous infusion of 500 mg and 1 g of paracetamol is about 15 &mu;g/ml and 30 &mu;g/ml, respectively.</p><p><em>Distribution</em></p><p style="margin-left:0cm; margin-right:10.8pt">The volume of distribution of paracetamol is approximately 1 l/kg. Paracetamol is not extensively bound to plasma proteins (about 10 %). Twenty minutes following infusion of 1 g paracetamol, significant concentrations of paracetamol (about 1.5 &micro;g/ml) were observed in the cerebrospinal fluid.</p><p><em>Biotransformation</em></p><p style="margin-right:18.0pt">Paracetamol is mainly metabolised in the liver following two major hepatic pathways: conjugation with glucuronic acid and sulphuric acid. At doses that exceed the therapeutic dose, the latter route is rapidly saturated. A small fraction (less than 4 %) is metabolised by cytochrome P450 to a reactive intermediate (N-acetyl benzoquinone imine) which, with normal dosing, is rapidly detoxified by reduced glutathione and eliminated in the urine after conjugation with cysteine and mercapturic acid. However, in the event of massive overdose, the quantity of this toxic metabolite is increased.</p><p><em>Elimination</em></p><p style="margin-right:18.0pt">The metabolites of paracetamol are mainly excreted in the urine. 90 % of the dose administered is excreted within 24 hours, mainly as glucuronide (60-80 %) and sulphate (20-30 %) conjugates. Less than 5 % is eliminated unchanged. Plasma half-life is 2.7 hours and total body clearance is 18 l/h.</p><p><u>Newborn infants, infants and children </u></p><p style="margin-left:0cm; margin-right:10.8pt">The pharmacokinetic parameters of paracetamol observed in infants and children are similar to those observed in adults, except for the plasma half-life that is slightly shorter (1.5 to 2 hours) than in adults. In newborn infants, the plasma half-life is longer than in infants, i.e. around 3.5 hours. Newborn infants, infants and children up to 10 years excrete significantly less glucuronide and more sulphate conjugates than adults.</p><p style="margin-left:0cm; margin-right:0cm">Table: Age related pharmacokinetic values (standardised clearance, *CLstd/Foral (l.h<sup>-1</sup> 70 kg<sup>-1</sup>)</p><table cellspacing="0" cellpadding="0" border="0"><tbody><tr><td style="background-color:#e6e6e6; border-color:black; height:19.9pt; width:147.6pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center"><strong>Age</strong></p></td><td style="background-color:#e6e6e6; border-color:black; height:19.9pt; width:120.0pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center"><strong>Weight (kg)</strong></p></td><td style="background-color:#e6e6e6; border-color:black; height:19.9pt; width:120.95pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center"><strong>CL</strong><strong>std</strong><strong>/F</strong><strong>oral </strong><strong>(l.h<sup>-1</sup> 70 kg<sup>-1</sup>)</strong></p></td></tr><tr><td style="border-color:black; height:19.45pt; width:147.6pt"><p style="margin-left:4.55pt; margin-right:0cm">40 weeks (age post conception)</p></td><td style="height:19.45pt; width:120.0pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center">3.3</p></td><td style="height:19.45pt; width:120.95pt"><p style="margin-left:0cm; margin-right:0cm">5.9</p></td></tr><tr><td style="border-color:black; height:19.45pt; width:147.6pt"><p style="margin-left:4.55pt; margin-right:0cm">3 months (age postnatal)</p></td><td style="height:19.45pt; width:120.0pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center">6</p></td><td style="height:19.45pt; width:120.95pt"><p style="margin-left:0cm; margin-right:0cm">8.8</p></td></tr><tr><td style="border-color:black; height:19.45pt; width:147.6pt"><p style="margin-left:4.55pt; margin-right:0cm">6 months (age postnatal)</p></td><td style="height:19.45pt; width:120.0pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center">7.5</p></td><td style="height:19.45pt; width:120.95pt"><p style="margin-left:0cm; margin-right:0cm">11.1</p></td></tr><tr><td style="border-color:black; height:19.45pt; width:147.6pt"><p style="margin-left:4.55pt; margin-right:0cm">1 year (age postnatal)</p></td><td style="height:19.45pt; width:120.0pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center">10</p></td><td style="height:19.45pt; width:120.95pt"><p style="margin-left:0cm; margin-right:0cm">13.6</p></td></tr><tr><td style="border-color:black; height:19.4pt; width:147.6pt"><p style="margin-left:4.55pt; margin-right:0cm">2 years (age postnatal)</p></td><td style="height:19.4pt; width:120.0pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center">12</p></td><td style="height:19.4pt; width:120.95pt"><p style="margin-left:0cm; margin-right:0cm">15.6</p></td></tr><tr><td style="border-color:black; height:19.45pt; width:147.6pt"><p style="margin-left:4.55pt; margin-right:0cm">5 years (age postnatal)</p></td><td style="height:19.45pt; width:120.0pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center">20</p></td><td style="height:19.45pt; width:120.95pt"><p style="margin-left:0cm; margin-right:0cm">16.3</p></td></tr><tr><td style="border-color:black; height:20.15pt; width:147.6pt"><p style="margin-left:4.55pt; margin-right:0cm">8 years (age postnatal)</p></td><td style="height:20.15pt; width:120.0pt"><p style="margin-left:0cm; margin-right:0cm; text-align:center">25</p></td><td style="height:20.15pt; width:120.95pt"><p style="margin-left:0cm; margin-right:0cm">16.3</p></td></tr></tbody></table><p>&nbsp;</p><p style="margin-left:183.6pt; margin-right:0cm"><!--[if gte vml 1]><v:line
 id="_x0000_s1026" style='position:absolute;left:0;text-align:left;z-index:251657728;
 mso-position-horizontal-relative:page;mso-position-vertical-relative:page'
 from="68.5pt,781.7pt" to="526.55pt,781.7pt" strokeweight=".7pt">
 <w:wrap anchorx="page" anchory="page"/>
</v:line><![endif]--><!--[if !vml]--><img src="file:///C:/Users/test/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" width="613" height="2" /><!--[endif]-->C O N F I D E N T I A L&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Page 7</p><p>&nbsp;</p><p style="margin-left:0cm; margin-right:0cm"><strong>1.3.1 SPC, Labelling and Package Leaflet</strong></p><p><!--[if gte vml 1]><v:line id="_x0000_s1027" style='position:absolute;
 z-index:251658752;mso-position-horizontal-relative:page;
 mso-position-vertical-relative:page' from="68.5pt,69.1pt" to="526.55pt,69.1pt"
 strokeweight=".5pt">
 <w:wrap anchorx="page" anchory="page"/>
</v:line><![endif]--><!--[if !vml]--><img src="file:///C:/Users/test/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" width="613" height="2" /><!--[endif]--><sup>*</sup>CLstd is the population estimate for CL<br /><u>Special population</u></p><p><em>Renal insufficiency</em></p><p style="margin-right:3.6pt">In severe renal impairment (creatinine clearance 10-30 ml/min), the elimination of paracetamol is slightly delayed, the elimination half-life ranging from 2 to 5.3 hours. For the glucuronide and sulphate conjugates, the elimination rate is 3 times lower in subjects with severe renal impairment than in healthy subjects. Therefore, when giving paracetamol to patients with severe renal impairment (creatinine clearance &le;30 ml/min), the minimum interval between each administration should be increased to 6 hours (see section 4.2).</p><p><em>Elderly</em></p><p>The pharmacokinetics and metabolism of paracetamol are not altered in elderly. No dose adjustment</p><p>is required in this patient population.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0cm; margin-right:3.6pt">Preclinical data reveal no special hazard for humans beyond the information included in other sections of the SmPC. Studies on local tolerance of paracetamol solution for infusion in rats and rabbits showed good tolerability. Absence of delayed contact hypersensitivity has been tested in guinea pigs.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cysteine</p><p>Mannitol (E421)</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0cm; margin-right:18.0pt">This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Vial or bag before opening 
24 months
After first opening
Chemical and physical in-use stability has been demonstrated for 24 hours at room temperature.
From a microbiological point of view, he product should be used immediately.
If diluted in 0.9% sodium chloride or 5% glucose, the solution should also be used immediately.
However, if the solution is not used immediately, do not store for more than 1 hour “infusion time included

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not refrigerate or freeze.</p><p>For storage conditions of the diluted medicinal product, see section 6.3</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0cm; margin-right:21.6pt">50 ml and 100 ml Type II glass vials closed with halobutyl stoppers and aluminium/plastic flip-off caps.</p><p style="margin-left:0cm; margin-right:18.0pt">50 ml and 100 ml bags with the primary film, administration port (infusion port) and addition port (injection port) consisting of a polyolefin housing and an over pouch consisting of aluminium and containing an oxygen scavenger. The bags are closed with polyisoprene stoppers and polypropylene caps.</p><p>Pack sizes:<br />1 vial</p><p>10 vials<br />12 vials<br />20 vials<br />20 bags<br />50 bags<br />60 bags</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Handling</u></p><p style="margin-left:0cm; margin-right:14.4pt">As for all solutions for infusion presented in glass vials or bags, it should be remembered that close monitoring is needed notably at the end of the infusion, regardless of infusion route. This monitoring at the end of the infusion applies particularly for central route infusions, in order to avoid air embolism.</p><p><u>Compatibility </u>&nbsp;</p><p style="margin-left:0cm; margin-right:32.4pt">Paracetamol 10 mg/ml solution for infusion can be diluted in sodium chloride 9 mg/ml (0.9 %) solution or 50 mg/ml glucose (5 %) solution up to one tenth (one volume Paracetamol 10 mg/ml solution for infusion into nine volumes diluent).</p><p style="margin-left:0cm; margin-right:54.0pt">The diluted solution should be visually inspected and should not be used in the presence of opalescence, visible particulate matter or precipitate.</p><p><u>Disposal </u>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local</p><p>requirements.</p><p style="margin-left:0cm; margin-right:43.2pt">Before administration, the product should be visually inspected for any particulate matter and discoloration. For single use only. Any unused solution should be discarded.</p><p style="margin-left:0cm; margin-right:14.4pt">The diluted solution should be visually inspected and should not be used in presence of opalescence, visible particulate matters or precipitate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Fresenius Kabi Deutschland GmbH 
D-61346 Bad Homburg v.d.H

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                07/2015
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>